Table 3.
Molecular characteristics of patients with AML according to mutational status of mitochondrial ETC genes. P-values calculated using Fisher’s Exact test.
| Gene | No Mutations (n = 184) | Mutations (n = 16) | p-value |
|---|---|---|---|
| FLT3 | 53 (8.8%) | 3 (18.8%) | 0.56 |
| TP53 | 11 (5.98%) | 5 (31.3%) | 0.004 |
| DNMT3A | 45 (24.5%) | 4 (25%) | >0.99 |
| CEBPA | 11 (5.98%) | 2 (12.5%) | 0.28 |
| NRAS | 15 (8.15%) | 0 | 0.62 |
| TET2 | 16 (8.70%) | 1 (6.25%) | >0.99 |
| IDH1 | 18 (9.78%) | 1 (6.25%) | >0.99 |
| IDH2 | 18 (9.78%) | 2 (12.5%) | 0.67 |
| RUNX1 | 16 (8.70%) | 1 (6.25%) | >0.99 |
| NPM1 | 51 (27.7%) | 3 (18.8%) | 0.57 |
| WT1 | 12 (6.52%) | 0 | 0.60 |